Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Doxorubicin hydrochloride liposome · Oncology
  Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity.
• Hemoporfin · Other
• Hemoporfin PDT · Oncology
  Hemoporfin is a photosensitizer that generates reactive oxygen species upon light activation to destroy tumor cells in photodynamic therapy.

Phase 3 pipeline

• FDA018-ADC · Oncology
  FDA018-ADC is an antibody-drug conjugate that delivers cytotoxic payload to target cells expressing specific tumor antigens.

Phase 2 pipeline

• Aminolaevulinic acid · Oncology
  Aminolaevulinic acid is a precursor to porphobilinogen, which is involved in the biosynthesis of heme.
• Aminolaevulinic acid photodynamic therapy · Oncology
  Aminolaevulinic acid acts as a precursor to porphyrin, which accumulates in cancer cells and is activated by light to produce reactive oxygen species, inducing cell death.
• FDA022-BB05

Phase 1 pipeline

• ALA 10%
• ALA 2.5%
• ALA 5%
• deuteporfin · Other
• F0002-ADC
• FZ-AD004
• FZ-AD005
• FZJ-003

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. portfolio CI brief
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. pipeline updates RSS